Compare YieldMax AMZN Option Income Strategy ETF (AMZY) vs DexCom, Inc. (DXCM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax AMZN Option Income Strategy ETF vs DexCom, Inc. — how do they compare? YieldMax AMZN Option Income Strategy ETF trades at $11.29, while DexCom, Inc. trades at $90.27 (market cap $33.79B). The key difference: DexCom, Inc. is trading nearer its 52-week high, YieldMax AMZN Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| AMZY | DXCM | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $15.75 | $89.53 |
52-Week Low | $9.98 | $54.84 |
Market Cap | — | $33.79B |
Enterprise Value | — | $33.24B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMZY trades at $11.35, down 2.32% today, with a bullish technical signal from moving averages but neutral oscillators. The ETF has paid consistent weekly dividends, with recent distributions ranging from $0.06 to $0.14 per share. Key resistance and support levels are clustered around $12 and $11, respectively, indicating a tight trading range.
Outlook is cautious due to concerns over NAV erosion from its synthetic option strategy, as highlighted by Seeking Alpha. While high yields attract income seekers, the strategy may cap upside and amplify downside risk. Investors should weigh the income benefits against potential long-term underperformance relative to Amazon.
DXCM trades at $90.23, up 2.94% today and near its 52-week high, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating EPS estimates with $0.70 versus $0.61 expected, and raised full-year guidance. Revenue growth remains robust at 13% year-over-year, supported by G7 system adoption and international expansion. Profit margins improved, with net income margin reaching 20.12% in 2025. Analyst sentiment is overwhelmingly positive, with 80% buy ratings.
The outlook for DXCM is favorable due to sustained demand for continuous glucose monitors and strategic initiatives like 'Road to 100'. Key risks include competitive pressures, regulatory scrutiny, and valuation multiples above industry averages. The stock's current price is slightly above the consensus target of $88.65, suggesting near-term consolidation may occur before further upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About YieldMax AMZN Option Income Strategy ETF
AMZY is an actively managed ETF that seeks to generate monthly income by selling call options on Amazon (AMZN) stock. It aims to provide high yield while maintaining exposure to the price movements of the e-commerce giant.
Read more on AMZY →About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →
